Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.40
ACT's Cash-to-Debt is ranked lower than
74% of the 790 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.44 vs. ACT: 0.40 )
Ranked among companies with meaningful Cash-to-Debt only.
ACT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.4 Max: 25.09
Current: 0.4
0.02
25.09
Equity-to-Asset 0.63
ACT's Equity-to-Asset is ranked higher than
50% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. ACT: 0.63 )
Ranked among companies with meaningful Equity-to-Asset only.
ACT' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.27  Med: 0.58 Max: 0.75
Current: 0.63
0.27
0.75
WACC vs ROIC
8.24%
-0.51%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -12.08
ACT's Operating Margin % is ranked lower than
79% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.64 vs. ACT: -12.08 )
Ranked among companies with meaningful Operating Margin % only.
ACT' s Operating Margin % Range Over the Past 10 Years
Min: -36.27  Med: 6.95 Max: 14.13
Current: -12.08
-36.27
14.13
Net Margin % 100.04
ACT's Net Margin % is ranked higher than
99% of the 737 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.21 vs. ACT: 100.04 )
Ranked among companies with meaningful Net Margin % only.
ACT' s Net Margin % Range Over the Past 10 Years
Min: -28.83  Med: 5.67 Max: 102.76
Current: 100.04
-28.83
102.76
ROE % 18.53
ACT's ROE % is ranked higher than
80% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.92 vs. ACT: 18.53 )
Ranked among companies with meaningful ROE % only.
ACT' s ROE % Range Over the Past 10 Years
Min: -11.23  Med: 7.32 Max: 19.24
Current: 18.53
-11.23
19.24
ROA % 10.84
ACT's ROA % is ranked higher than
79% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. ACT: 10.84 )
Ranked among companies with meaningful ROA % only.
ACT' s ROA % Range Over the Past 10 Years
Min: -4.32  Med: 4.03 Max: 22.05
Current: 10.84
-4.32
22.05
ROC (Joel Greenblatt) % -35.31
ACT's ROC (Joel Greenblatt) % is ranked lower than
78% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.01 vs. ACT: -35.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ACT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -112.05  Med: 20.42 Max: 38.44
Current: -35.31
-112.05
38.44
3-Year Revenue Growth Rate 27.40
ACT's 3-Year Revenue Growth Rate is ranked higher than
90% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. ACT: 27.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ACT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -14  Med: 16.2 Max: 27.4
Current: 27.4
-14
27.4
3-Year EBITDA Growth Rate 40.20
ACT's 3-Year EBITDA Growth Rate is ranked higher than
85% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.50 vs. ACT: 40.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ACT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -39.9  Med: 3.6 Max: 40.2
Current: 40.2
-39.9
40.2
3-Year EPS without NRI Growth Rate -1.20
ACT's 3-Year EPS without NRI Growth Rate is ranked lower than
63% of the 539 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.30 vs. ACT: -1.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ACT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -27.1  Med: -0.1 Max: 19.7
Current: -1.2
-27.1
19.7
GuruFocus has detected 5 Warning Signs with Allergan PLC $ACT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ACT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with ACT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Allergan PLC

SymbolPriceYieldDescription
AGNPRA857.806.385 1/2 % Cum.Conv.Pref.Shs 2015-1.3.18 Series -A-

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412 
Compare:OTCPK:TKPYY, NYSE:TEVA, NYSE:ZTS, NAS:MYL, OTCPK:SGIOF, OTCPK:ESALY, OTCPK:MKGAY, NYSE:PRGO, OTCPK:MTZPY, OTCPK:APNHY, OTCPK:SFOSF, OTCPK:HLUYY, NYSE:RDY, OTCPK:IPSEY, OTCPK:HKMPY, NYSE:MNK, NYSE:VRX, OTCPK:HYPMY, NAS:OPK, NYSE:TARO » details
Traded in other countries:A60.Germany, AGN N.Mexico,
Allergan PLC is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and distributing generic, brand and biosimilar products.

Allergan PLC, formerly known as Actavis PLC was incorporated in Ireland on May 16, 2013. It is an integrated specialty pharmaceutical company. The Company is engaged in development, manufacturing, marketing, sale and distribution of generic, branded generic, brand name, biosimilar and over-the-counter pharmaceutical products. It also develops and out-license generic pharmaceutical products in Europe through its Medis third-party business. It operates in three segments, Pharma, Specialty Brands and Anda Distribution. The Pharma segment includes off-patent pharmaceutical products that are therapeutically equivalent to proprietary products. The Specialty Brands segment includes patent-protected products and certain trademarked off-patent products that the Company sells and markets as brand pharmaceutical products. The Anda Distribution segment distributes generic and brand pharmaceutical products manufactured by third parties, as well as by the Company to independent pharmacies, pharmacy chains, pharmacy buying groups and physicians' offices. It competes with generic manufacturers of pharmaceutical products. It is subject to extensive, complex and evolving regulation by the federal government, the FDA, and to a lesser extent, by the U.S. Drug Enforcement Administration Occupational Safety and Health Administration and state government agencies, as well as by various regulatory agencies in foreign countries where its products or product candidates are being manufactured and/or marketed. The Federal Food, Drug and Cosmetic Act, the Controlled Substances Act and other federal statutes and regulations govern or influence the testing, manufacturing, packing, labeling, storing, record keeping, safety, approval, advertising, promotion, sale and distribution of its products.

Guru Investment Theses on Allergan PLC

Vanguard Health Care Fund Comments on Actavis PLC - Mar 27, 2015

Actavis (ACT) is a specialty pharmaceutical company that develops generic and branded products. We owned Actavis prior to its Forest Labs acquisition but increased our position. We are attracted to the uniqueness of the combined company’s business model, which provides exposure to both generic and branded pharmaceuticals globally. The company’s Irish tax rate could also be strategically important in future mergers and acquisitions. Actavis was the fund’s second-largest holding as of the end of the period.



From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report.



Check out Vanguard Health Care Fund latest stock trades

Ratios

vs
industry
vs
history
PE Ratio 6.61
ACT's PE Ratio is ranked higher than
94% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.40 vs. ACT: 6.61 )
Ranked among companies with meaningful PE Ratio only.
ACT' s PE Ratio Range Over the Past 10 Years
Min: 5.07  Med: 25.06 Max: 366.63
Current: 6.61
5.07
366.63
Forward PE Ratio 15.46
ACT's Forward PE Ratio is ranked higher than
50% of the 88 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.46 vs. ACT: 15.46 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 4.32
ACT's Price-to-Owner-Earnings is ranked higher than
95% of the 300 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.72 vs. ACT: 4.32 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ACT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.31  Med: 18.51 Max: 1279.04
Current: 4.32
3.31
1279.04
PB Ratio 1.22
ACT's PB Ratio is ranked higher than
84% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.02 vs. ACT: 1.22 )
Ranked among companies with meaningful PB Ratio only.
ACT' s PB Ratio Range Over the Past 10 Years
Min: 0.87  Med: 1.74 Max: 5.9
Current: 1.22
0.87
5.9
PS Ratio 6.35
ACT's PS Ratio is ranked lower than
71% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.06 vs. ACT: 6.35 )
Ranked among companies with meaningful PS Ratio only.
ACT' s PS Ratio Range Over the Past 10 Years
Min: 0.99  Med: 1.84 Max: 17.57
Current: 6.35
0.99
17.57
Price-to-Free-Cash-Flow 78.18
ACT's Price-to-Free-Cash-Flow is ranked lower than
84% of the 226 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.72 vs. ACT: 78.18 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ACT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.62  Med: 15.16 Max: 78.18
Current: 78.18
6.62
78.18
Price-to-Operating-Cash-Flow 65.11
ACT's Price-to-Operating-Cash-Flow is ranked lower than
88% of the 295 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.98 vs. ACT: 65.11 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ACT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.97  Med: 12.56 Max: 65.11
Current: 65.11
5.97
65.11
EV-to-EBITDA 22.13
ACT's EV-to-EBITDA is ranked lower than
64% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.72 vs. ACT: 22.13 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -224.1  Med: 11.7 Max: 386.1
Current: 22.13
-224.1
386.1
Shiller PE Ratio 55.15
ACT's Shiller PE Ratio is ranked lower than
60% of the 158 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 47.37 vs. ACT: 55.15 )
Ranked among companies with meaningful Shiller PE Ratio only.
ACT' s Shiller PE Ratio Range Over the Past 10 Years
Min: 18.96  Med: 54.31 Max: 2307.73
Current: 55.15
18.96
2307.73
Days Inventory 157.94
ACT's Days Inventory is ranked lower than
70% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.19 vs. ACT: 157.94 )
Ranked among companies with meaningful Days Inventory only.
ACT' s Days Inventory Range Over the Past 10 Years
Min: 75.66  Med: 121.54 Max: 369.82
Current: 157.94
75.66
369.82
Days Sales Outstanding 58.49
ACT's Days Sales Outstanding is ranked higher than
66% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.32 vs. ACT: 58.49 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.05  Med: 60.25 Max: 197.04
Current: 58.49
39.05
197.04
Days Payable 49.30
ACT's Days Payable is ranked lower than
68% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.12 vs. ACT: 49.30 )
Ranked among companies with meaningful Days Payable only.
ACT' s Days Payable Range Over the Past 10 Years
Min: 28.03  Med: 76.38 Max: 109.48
Current: 49.3
28.03
109.48

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -29.10
ACT's 3-Year Average Share Buyback Ratio is ranked lower than
87% of the 436 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. ACT: -29.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -45.6  Med: -6 Max: 2
Current: -29.1
-45.6
2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 1.22
ACT's Price-to-Tangible-Book is ranked higher than
86% of the 747 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.65 vs. ACT: 1.22 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ACT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.03  Med: 7.62 Max: 250.29
Current: 1.22
1.03
250.29
Price-to-Intrinsic-Value-Projected-FCF 1.17
ACT's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
82% of the 320 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. ACT: 1.17 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ACT' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.6  Med: 1.19 Max: 2.96
Current: 1.17
0.6
2.96
Price-to-Median-PS-Value 3.45
ACT's Price-to-Median-PS-Value is ranked lower than
91% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. ACT: 3.45 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ACT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.67  Med: 1.47 Max: 5.54
Current: 3.45
0.67
5.54
Earnings Yield (Greenblatt) % -1.40
ACT's Earnings Yield (Greenblatt) % is ranked lower than
72% of the 835 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. ACT: -1.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1.4  Med: 6.1 Max: 12.3
Current: -1.4
-1.4
12.3
Forward Rate of Return (Yacktman) % 7.36
ACT's Forward Rate of Return (Yacktman) % is ranked lower than
54% of the 358 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.67 vs. ACT: 7.36 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ACT' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -5.2  Med: 7.4 Max: 16.1
Current: 7.36
-5.2
16.1

More Statistics

Short Percentage of Float1.14%
52-Week Range $201.91 - 317.72
Shares Outstanding (Mil)392.44
» More Articles for ACT

Headlines

Articles On GuruFocus.com
David Tepper Invests Heavily in Pharma in 4th Quarter Feb 16 2017 
Where Seth Klarman Sees Value in Today’s Market Feb 15 2017 
Daniel Loeb Drops Pharma, Picks Up Rate-Sensitive Financials Feb 13 2017 
How BioVie, Conatus and PhaseRX Tackle Liver Diseases Feb 08 2017 
Daniel Loeb's Third Point Hedge Fund 4th Quarter Commentary Feb 02 2017 
Weitz Funds Comments on Allergan Jan 26 2017 
Teva Is a Hold Nov 30 2016 
Weekly CEO Buys Highlight Nov 29 2016 
Weekly Top Insider Buys Highlight for Week of Nov. 18 Nov 19 2016 
John Griffin Expands Portfolio in 3rd Quarter Nov 16 2016 

More From Other Websites
Top Research Reports for February 24, 2017 Feb 24 2017
Allergan CEO Pushes for Trump to Lead Drug Price Discussions Feb 22 2017
The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan,... Feb 21 2017
[$$] Big pharma bets billions on 'silent' liver disease Feb 21 2017
Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ Feb 17 2017
David Tepper Invests Heavily in Pharma in 4th Quarter Feb 16 2017
5 Ways Allergan Can Keep Up Momentum Feb 15 2017
Billionaire Dan Loeb’s Biggest Q4 Moves Include Bank-Buying Spree, Selling Allergan (AGN) Feb 15 2017
David Tepper's Appaloosa just dropped about $1 billion on 4 pharma stocks Feb 14 2017
Appaloosa Management snaps up Allergan shares in 4th quarter Feb 14 2017
Hologic Follows Allergan, Buying Body-Sculptor Cynosure For $1.65 Bil Feb 14 2017
Valeant, Pershing Square to Split Legal Fees on Allergan Lawsuit Feb 14 2017
Botox-maker Allergan is betting that zapping your fat is worth $4 billion Feb 14 2017
Allergan To Acquire ZELTIQ in $2.47 Billion Deal, ZELTIQ Shares Pop 13% Feb 13 2017
Allergan to buy fat-fighter Zeltiq Aesthetics for $2.48 billion Feb 13 2017
Allergan to buy fat-fighter Zeltiq Aesthetics for $2.48 billion Feb 13 2017
Allergan to buy fat-fighter Zeltiq Aesthetics for $2.48 bln Feb 13 2017
Allergan To Buy Fat-Freezing Zeltiq For $2.5 Bil; Zeltiq Hits Record High Feb 13 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)